Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Q2 2016 Earnings Presentation

10 slides from Lumos Pharma's earnings presentation, Jul 29, 2016

  1. Slide 1: Second Quarter 2016 Financial Results

    NewLink Genetics Corporation Nasdaq: NLNK July 29, 2016 Second Quarter 2016 Financial Results

  2. Slide 2: Agenda

    Agenda 2 Introduction  Jack Henneman, Executive Vice President & CFO 2016 Ongoing Priorities  Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates  Nicholas N. Vahanian, M.D., President & CMO Restructuring & Second Quarter 2016 Financial Results  Mr. Henneman

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w

  4. Slide 4: NewLink Genetics: Building a Leading Immuno-Oncology Company

    4 Oncology Focused Pipeline  Two IDO pathway inhibitors in clinical development (indoximod and GDC-0919)  Research collaboration with Genentech for IDO and TDO inhibitors  Small molecule program focused on additional immuno-oncology targets Strong Scientific and Business Leadership  Executing on

  5. Slide 5: Ongoing Priorities

    5  Progress and accelerate the development of indoximod  Continue Genentech and Merck alliances  Advance PTEN and Zika  Evaluate external opportunities for pipeline expansion Ongoing Priorities

  6. Slide 6: NewLink Genetics' IDO Pathway Inhibitors

    NewLink Genetics’ IDO Pathway Inhibitors 6 AGENT INDICATION DESIGN STATUS Indoximod Breast cancer (metastatic) Indoximod + taxane; randomized Pancreatic cancer (metastatic) Indoximod + gemcitabine and nab-paclitaxel Glioblastoma multiforme Indoximod + temozolomide Melanoma (advanced) Indoximod + ipi

  7. Slide 7: 2016-2018 Cash Conservation Initiatives

    7 Conserve cash  Wind-down HyperAcute Cellular Immunotherapy trials and manufacturing activities  Carefully planned company-wide headcount reductions to ~130  Consolidate/scale-back facilities footprint  Eliminate commercialization spending  Capital spending reduced to primarily supporting R&D

  8. Slide 8: "Before and After" Summary

    8 Substantial cash runway Before After Headcount ~230 ~130 Facilities 133K sq ft 66K sq ft Annual Lease Cost $1.4mm $0.8mm Clinical Trials 19 (finish 15 existing, 4 new) 4-8 Quarterly Negative Cash- flow ~$20mm ~$12 mm Quarters of Cash ~8 10+ “Before and After” Summary

  9. Slide 9: Second Quarter 2016 Financial Results

    Second Quarter 2016 Financial Results 9 Jack Henneman, EVP and Chief Financial Officer Strong Capital Position  Stable and reliable cash position - $160.5M at Q2 2016 / $197.8M at YE 2015  Goal and expectation to finish 2016 with two years of cash-on-hand Multiple Value Drivers Capacity for Increm

  10. Slide 10: Brewin

    Brewin A

NewLink Genetics — Q2 2016 Earnings Presentation on 6ix